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                                In the early 1980s, Spain was among the European countries with 
the lowest incidence of breast cancer (  1  ). However, it experienced 
a sharp increase in disease incidence over the subsequent decades 
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     Background     Since the 1980s, Spain experienced two decades of sharply increasing breast cancer incidence. Declines 
in breast cancer incidence have recently been reported in many developed countries. We examined 
whether a similar downturn might have taken place in Spain in recent years.   
     Methods     Cases of invasive female breast cancer were drawn from all population-based Spanish cancer registries 
that had at least 10 years of uninterrupted registration over the period 1980  –  2004. Overall and age-specific 
changes in incidence rates were evaluated using change-point Poisson models, which allow for accurate 
detection and estimation of trend changes. All statistical tests were two-sided.   
     Results     A total of 80    453 incident cases of invasive breast cancer were identified. Overall age- and registry-adjusted 
incidence rates rose by 2.9% (95% confidence interval [CI] = 2.7% to 3.1%) annually during the 1980s and 
1990s; there was a statistically significant change in this trend in 2001 (95% CI = 1998 to 2004;   P   value for the 
existence of a change point <.001), after which incidence declined annually by 3.0% (95% CI = 1.8% to 4.1%). 
This trend differed by age group: There was a steady increase in incidence for women younger than 45 years, 
an abrupt downturn in 2001 for women aged 45  –  64 years, and a gradual leveling off in 1995 for women aged 
65 years or older. Separate analyses for registries that had at least 15 years of uninterrupted registration 
detected a statistically significant interruption of the previous upward trend in breast cancer incidence in 
provinces that had aggressive breast cancer screening programs and high screening participation rates, in-
cluding Navarra (change point = 1991,   P   < .001), Granada (change point = 2002,   P   = .003), Bizkaia (change 
point = 1998,   P   < .001), Gipuzkoa (change point = 1998,   P   = .001), and Araba (change point = 1997,   P   = .002).   
     Conclusions     The recent downturn in breast cancer incidence among Spanish women older than 45 years is best 
explained by a period effect linked to screening saturation.   
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(  1    –    3  ). A variety of factors were associated with this marked rising 
trend, including the dramatic decline in fertility (  4  ), the increasing 
prevalence of obesity (  5  ,  6  ), and the high prevalence of sedentary 
lifestyle and alcohol consumption in the Spanish population (  7  ). 
  A downturn in breast cancer incidence in the early 2000s has 
been reported in several developed countries, including the United 
States (  8    –    11  ), Canada (  12  ), Germany (  13  ), Australia (  14  ), New 
Zealand (  15  ), Norway (  16  ), France (  17  ), and Italy (  18  ). To examine 
whether a similar downward trend might have occurred in Spain in 
recent years, we analyzed changes in breast cancer incidence in 
Spain over the period 1980 through 2004. Given the differential 
impact of breast cancer screening programs on age-speciﬁ  c inci-
dence rates and the use of hormone replacement therapy (HRT) 
in postmenopausal women, we also analyzed trends in breast can-
cer incidence separately for women aged 25  –  44 years, those aged 
45  –  64 years, and those 65 years or older. 
    Methods 
    Data Source 
  The number of cases of invasive female breast cancer, broken down 
by 5-year age-at-diagnosis group (0  –  4, 5  –  9,   . . .  , 80  –  84, and   ≥  85 
years) and by the calendar year of diagnosis, was obtained from the 
16 population-based cancer registries in Spain that participate in 
the European Network of Cancer Registries and have collected data 
for at least 10 consecutive years over the period 1980  –  2004. Cases 
of invasive female breast cancer corresponded to code 174 from the 
  International Classification of Diseases, Ninth Revision   (  19  ) and code 
C50 from the   International Classification of Diseases, Tenth Revision   
(  20  ). Overall, the 16 registries included in this study cover approxi-
mately 26% of the total female population of Spain (5    298    119 
women covered in 2001) and serve 17 Spanish provinces that are 
located mainly in the east of the country along an area that runs 
from the northern Cantabrian coast to the southern Mediterranean 
region. Estimates of the midyear (ie, July 1) female populations 
covered by these registries during 1980  –  2004 were obtained from 
the Spanish National and Regional Institutes of Statistics.   
    Statistical Analysis 
  Age-adjusted breast cancer incidence rates were calculated for each 
registry and 5-year period (1980  –  1984, 1985  –  1989, 1990  –  1994, 
1995  –  1999, and 2000  –  2004) by using the direct method (  21  ) and 
the European standard population as the reference population. We 
computed the age-adjusted incidence rate ratios and 95% confi-
dence intervals (CIs) for each individual registry with respect to all 
registries combined in each 5-year period by assuming a Poisson 
distribution for the number of cases. 
  Age- and registry-adjusted changes in incidence rates over the study 
period were evaluated by using log-linear Poisson models (  22  ). More 
speciﬁ  cally, the number of invasive breast cancer cases,   d  apr    , diagnosed 
at age   a   in year   p   and recorded in registry   r   was assumed to follow a 
Poisson distribution with mean          apr  n  apr     and free dispersion parameter      , 
where          apr     is the underlying incidence rate and   n  apr     is the number of 
woman-years at risk. The effects of age at diagnosis, calendar year of 
diagnosis, and registry on the log rate were assumed to be additive,
    λρ α   log( ) ( ), apr r a fp 
    CONTEXT AND CAVEATS 
    Prior knowledge 
  Breast cancer incidence in Spain has increased sharply since the 
1980s. However, it is unclear whether Spain is experiencing the 
recent declines in breast cancer incidence that has been reported 
in many developed countries.   
    Study design 
  Data from all population-based Spanish cancer registries that had 
at least 10 years of uninterrupted registration over the period 
1980  –  2004 were used to evaluate overall and age-specific changes 
in the incidence rates of invasive female breast cancer, taking into 
account the starting year of the corresponding breast cancer 
screening program for the population covered by the registry and 
the year in which the screening program achieved full coverage of 
the target population.   
    Contribution 
  Overall incidence rates increased during the 1980s and 1990s by 
2.9% annually until 2001, after which incidence declined annually by 
3.0%. There was a steady increase in incidence for women younger 
than 45 years, an abrupt downturn in 2001 for women aged 45  –  64 
years, and a gradual leveling off in 1995 for women aged 65 years 
or older.   
    Implications 
  The recent downturn in breast cancer incidence among Spanish 
women older than 45 years is best explained by a period effect 
linked to screening saturation.   
    Limitations 
  The observed trends in breast cancer incidence might not be gen-
eralizable to all parts of Spain. Regional differences in the timing of 
breast cancer screening program implementation are likely to have 
increased the heterogeneity in incidence trends across registries. 
Data quality differed slightly across registries in terms of case com-
pleteness and diagnostic accuracy. 
    From the Editors       
    
where          r     and          a     are the parameters associated with registry   r   and 
age group   a   and whose respective averages (weighted by the cor-
responding marginal number of woman-years) are constrained to 
be 0, and   f  (  p  ) is a predetermined parametric function of the year of 
diagnosis that includes an intercept term. Two alternative param-
eterizations were used for the function   f  (  p  ). First, to describe the 
observed temporal trend without imposing any particular func-
tional form, this function consisted of the usual indicator variables 
for each single year of diagnosis. Second, to formally detect and 
estimate changes in incidence rates over the study period, the func-
tion   f  (  p  ) consisted of two intersecting linear trends with a smooth 
transition at an unknown change point      ,
    ββ β τ γ

    W   
2
0 ( ) () () , fp p p  
where        0   is the intercept,        1                2   and        1   +        2   represent the period 
slopes below and above the change point          , respectively, and           is a 
transition parameter that controls the sharpness of the transition 
between the two linear trends at the change point          , allowing not 
only for abrupt changes but also for more gradual transitions. As 
      approaches 0, the function   f  (  p  ) converges to the usual two 1586   Articles | JNCI  Vol. 101, Issue 22  |  November 18, 2009
intersecting straight lines with a sharp bend at      ; that is,   f  (  p  ) =        0   
+ (       1                2  )(  p              ) if   p     ≤         and        0   + (       1   +        2  )(  p              ) if   p   >      . This 
change-point model was fitted by using a grid search over       and      , 
and the asymptotic   P   value of the test for the existence of a change 
point was corrected for the search made over       and       by applying 
the improved Bonferroni inequality (  23  ,  24  ). The model provided: 
1) the corrected   P   value of the test for the change point, 2) the 
estimate and 95% confidence interval for the location of the 
change point, and 3) the estimates and 95% confidence intervals 
for the annual percent change in incidence rate before and after 
the estimated change point. Further details on inference and 
testing procedures are provided elsewhere (  24  ). A program using R 
statistical software (R Foundation for Statistical Computing, 
Vienna, Austria) to fit the above change-point models is available 
in the     Supplementary     Material     (available online). 
  Because of the small number of breast cancers diagnosed in 
women younger than 25 years, this age group was excluded from 
all trend analyses. The above-described models were also used to 
evaluate the speciﬁ  c evolution of breast cancer incidence among 
women aged 25  –  44 years, those aged 45  –  64 years, and those 65 
years or older. These age cut points were chosen because all 
Spanish breast cancer screening programs initially targeted women 
aged 45  –  64 years or those aged 50  –  64 years, depending on the 
region. Finally, to explore possible geographic differences in breast 
cancer incidence trends, temporal trends were analyzed separately 
for the nine registries that had at least 15 years of uninterrupted 
registration. All statistical tests were two-sided.   P   values less than 
.05 were considered statistically signiﬁ  cant.     
    Results 
  A total of 80    453 incident cases of invasive breast cancer were iden-
tified among the 100    098    780 woman-years covered by the 16 Spanish 
registries from 1980 through 2004. Overall, the age-adjusted inci-
dence rate increased sharply from 54.7 cases per 100    000 woman-
years in 1980  –  1984 to 83.8 cases per 100    000 woman-years in 
2000  –  2004 (  Table 1  ). In general, the highest age-adjusted rates 
were observed in the northeastern provinces of Girona, Tarragona, 
and Navarra (rate ratios of 1.14, 1.11, and 1.09 with respect to 
all the registries combined for the period 2000  –  2004, respec-
tively), whereas the lowest rates were observed in the southeastern 
provinces of Cuenca, Albacete, Castelló, and Granada (rate ratios 
of 0.80, 0.85, 0.88, and 0.91, respectively). Nevertheless, these 
geographic differences in age-adjusted breast cancer incidence 
rates seemed to be narrowing between 1990  –  1994 and 2000  –  2004 
(ratio of the 75th to the 25th percentile of breast cancer incidence 
rate = 1.26 in 1990  –  1994, 1.18 in 1995  –  1999, and 1.15 in 2000  –
  2004). Detailed information on biennial age-adjusted rates 
for all 16 registries is provided in     Supplementary     Table     1     
(available online).         
    Figure 1   depicts age- and registry-adjusted breast cancer inci-
dence rates by calendar year of diagnosis for women aged 25 years 
or older included in all Spanish registries, along with the estimated 
temporal trend obtained by ﬁ  tting a change-point model. Although 
the incidence of invasive breast cancer increased steadily during 
the 1980s and 1990s, it appeared to decline in 2000  –  2004. The 
change-point model conﬁ  rmed this result, with a gradual but sta-
tistically signiﬁ  cant change in trend in 2001 (95% CI = 1998 to 
2004;   P   value for the existence of a change point < .001). The 
breast cancer incidence rate increased by 2.9% (95% CI = 2.7% to 
3.1%) per year until 2001 and thereafter declined by 3.0% (95% 
CI = 1.8% to 4.1%) per year.         
  We next analyzed breast cancer incidence trends by age group. 
There was no evidence of a change in trend among women aged 
25  –  44 years (  P   value for the existence of a change point = .99); the 
annual increase in incidence rate over the entire 1980  –  2004 period 
was 1.7% (95% CI = 1.4% to 2.1%) (  Figure 2  , A). Among women 
aged 45  –  64 years, however, we detected a statistically signiﬁ  cant 
and sharp decline in breast cancer incidence in 2001 (95% CI = 
2000 to 2002;   P   value for the existence of a change point <.001) 
(  Figure 2  , B). In this age group, breast cancer incidence increased 
at an annual rate of 3.4% (95% CI = 3.1% to 3.6%) until 2001 and 
then decreased sharply at an annual rate of 2.4% (95% CI = 0.7% 
to 4.0%). Among women aged 65 years or older, there was a 
gradual but statistically signiﬁ  cant leveling off in breast cancer 
incidence beginning in 1995 (95% CI = 1992 to 1999;   P   value 
for the existence of a change point <.001) (  Figure 2  , C). In this 
age group, the annual increase in incidence before 1995 was 
3.3% (95% CI = 2.8% to 3.7%); after 1995, incidence gradually 
stabilized (annual percent change =      0.4%, 95% CI =      1.0% 
to 0.1%).         
  We also examined temporal trends in age-adjusted incidence 
rates for registries that had at least 15 years of uninterrupted 
registration, taking into account the starting year of the corre-
sponding breast cancer screening program for the population 
covered by the registry and the year in which the screening pro-
gram achieved full coverage of the target population (  Table 2  ). 
We detected statistically signiﬁ  cant changes in breast cancer inci-
dence trends in Navarra (  P   < .001), Granada (  P   = .003), Bizkaia 
(  P   < .001), Gipuzkoa (  P   = .001), and Araba (  P   = .002), most of 
which are provinces that have aggressive breast screening pro-
grams (ie, the program reached full screening coverage in only 
1 or 2 years). The estimated change point in breast cancer inci-
dence for each of these provinces was very close to the full-
coverage year. The annual increases in incidence rates before the 
change point ranged from 3.3% to 5.1% and were followed by a 
long-term leveling off or a slight decline in incidence in Navarra, 
Bizkaia, Gipuzkoa, and Araba and a sharp but short-term decline 
in Granada. For the remaining provinces in which longer time 
spans were required to achieve full screening coverage, breast 
cancer incidence increased steadily by 1.9% to 2.9% per year 
across the entire study period.           
    Discussion 
  Our results show that the steady increase in breast cancer inci-
dence observed in Spain during the 1980s and 1990s has come to 
a halt in recent years and that changes in incidence in 2000  –  2004 
differed by age group. Among women aged 45  –  64 years, there was 
an abrupt downturn in incidence rates in 2001, whereas among 
women aged 65 years or older, the increasing trend gradually 
leveled off in 1995 and remained stable thereafter. Among women 
younger than 45 years, however, breast cancer incidence appeared 
to increase steadily across the entire study period. jnci.oxfordjournals.org    JNCI | Articles 1587
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  The results of this study are strengthened by the inclusion of 
the most recent available data from all population-based Spanish 
cancer registries with at least 10 years of uninterrupted registra-
tion, which resulted in more than 80    000 registered cases of inva-
sive breast cancer, as well as by the use of proper statistical methods 
to detect trend changes. 
  Nevertheless, several limitations must be considered when 
interpreting our ﬁ  ndings. First, the populations covered by the 
included registries are located mainly in the eastern part of Spain. 
Thus, the observed trends in breast cancer incidence might not be 
generalizable to the western and central parts of Spain. Second, 
breast cancer screening programs were implemented in the cor-
responding populations at different times during the 1990s, and 
they had highly heterogeneous time spans to achieve full coverage 
of the target population (1  –  9 years) and different participation 
rates (63%  –  88%). These regional differences are likely to have 
inﬂ  uenced breast cancer incidence by increasing heterogeneity in 
incidence trends across registries, and hence the resulting overall 
trend should be interpreted as a summary of breast cancer inci-
dence trends for the whole country. Third, differences in case 
completeness and diagnostic accuracy across registries may have 
distorted the observed trend. This potential problem may be of 
particular concern in 2000  –  2004, when we detected the disruption 
in the former rising trend. However, taking into account the most 
recent information available regarding the quality of breast cancer 
registration, the percentage of histologically veriﬁ  ed breast cancer 
cases was high in all Spanish registries during the 1996  –  2002 
period, ranging from 93% to 99%, whereas the percentage of 
breast cancer cases that were registered solely on the basis of death 
certiﬁ  cates was between 0.4% and 4% (  21  ). Finally, substantial 
reporting delays might have produced downwardly biased breast 
cancer incidence trends for the most recent years of diagnosis. 
However, in accordance with International Agency for Research 
on Cancer quality control procedures (  21  ), Spanish registries pro-
vided us with data only for the years for which they had complete 
case ascertainment from all information sources. As a result, the 
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    Figure 1       .       Age- and registry-adjusted incidence rates of invasive breast 
cancer over the period 1980  –  2004 among women aged 25 years or 
older included in all Spanish registries. The observed rates (  dotted line  ) 
were obtained by using nominal categories for each single calendar 
year of diagnosis, and the estimated temporal trend (  solid line  ) and its 
95% conﬁ  dence interval (  dashed lines  ) were obtained from ﬁ  tting a 
change-point model (see “Methods”).         
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  Figure 2    .       Age- and registry-adjusted incidence rates of invasive breast 
cancer over the period 1980  –  2004 among women who were included in 
all Spanish registries.   A  ) Women aged 25  –  44 years.   B  ) Women aged 
45  –  64 years.   C  ) Women aged 65 years or older. The observed rates 
(  dotted lines  ) were obtained by using nominal categories for each 
single calendar year of diagnosis, and the estimated temporal trends 
(  solid lines  ) and their 95% conﬁ   dence intervals (  dashed lines  ) were 
obtained from a log-linear model (A) and from change-point models 
(B and C) (see “Methods”).           
average percentage of cases added to or deleted from the registries 
after the closing date for the 1997  –  2002 period was only 1.3% and 
ranged from      0.3% in Araba to 3.3% in Girona; hence, case in-
completeness was expected to have little inﬂ  uence on the recent 
downturn in breast cancer incidence. jnci.oxfordjournals.org    JNCI | Articles 1589
  In this study we have proposed a new statistical approach to 
detect and estimate a change point in breast cancer incidence. 
Trend changes in incidence rates were evaluated by using transi-
tion change-point models (  24  ), which afford two methodological 
advantages over the widely used joinpoint regression approach 
(  25  ). First, instead of assuming an overall trend comprising inter-
secting linear segments with a sharp bend at the change point, the 
change-point model that we used includes a transition parameter 
that allows for abrupt changes as well as for more gradual transi-
tions between linear trends, the latter of which are more plausible 
in many epidemiological settings. Second, in transition change-
point models, changes in adjusted rates over time are obtained 
directly by ﬁ  tting Poisson models to the observed counts, which 
include a segmented period effect as well as age at diagnosis and 
registry as adjustment factors, rather than by using a segmented 
regression on the estimated adjusted rates. Nevertheless, our 
implementation of these transition models allows for only a single 
change point and the models should be extended further to enable 
multiple change points. 
  To interpret changes in breast cancer incidence, it is important 
to consider factors that might inﬂ  uence the observed trends. In 
most developed countries where a downturn in breast cancer inci-
dence has been reported, this decline has been associated with a 
decrease in the use of HRT (  8    –    11  ,  13    –    17  ). HRT use declined after 
the publication of results from the Women’s Health Initiative, the 
largest randomized trial ever designed to assess the risks and ben-
eﬁ  ts of HRT that included estrogen plus progestin regimens (  26  ). 
The trial was halted because more women in the experimental 
group than in the placebo group developed heart disease and inva-
sive breast cancer (  26  ). It has been argued that too little time has 
elapsed between the drop in HRT use and the decline in breast 
cancer incidence for a true causal relationship to be inferred 
(  27  ,  28  ). Nevertheless, epidemiological data showing sharp de-
creases in breast cancer risk within 1 year of stopping estrogen plus 
progestin therapy support a causal link (  29  ,  30  ). 
  Large differences in HRT use have been reported among post-
menopausal women in developed countries: The prevalence of 
HRT use was high in the 1990s in North America, Australia, and 
Western and Northern Europe and low in Central, Eastern, and 
Southern Europe (  31  ). Although the decline in HRT use seems to 
be associated with a decrease in breast cancer incidence in several 
countries (  8    –    11  ,  13    –    17  ), changes in HRT use appear to have con-
tributed very little to the breast cancer incidence trends observed 
in populations in which this treatment was not widespread 
(  18  ,  32  ,  33  ). A cross-national study in 1996 found that HRT was 
rarely used in Spain (  34  ). During the 1990s, the prevalence of 
HRT use among Spanish women aged 45  –  64 years increased pro-
gressively, reaching a high of 5.9% in 1998 (  35  ); however, by 2006, 
it had declined to 4.2% (  36  ). In addition, a study conducted in 
Spanish primary care settings in 1998 showed that 56% of post-
menopausal women on HRT received estrogens alone, whereas 
only 42% received combined estrogens with progestins (  35  ). 
Hence, it is unlikely that variations in HRT use have played a 
major role in the recent decline in breast cancer incidence among 
middle-aged Spanish women. 
  The other important explanatory factor to be considered when 
interpreting changes in breast cancer incidence is screening satu-
ration (  10  ,  27  ). All of the autonomous regions in Spain imple-
mented breast cancer screening programs during the 1990s, and 
although these programs mainly targeted women aged 50  –  64 
years, some also included women aged 45  –  49 years. In accordance 
with European guidelines (  37  ), most Spanish breast cancer 
screening programs have recently extended the target population 
to include women aged 65  –  69 years (  38  ). The introduction of 
screening programs perturbs preexisting trends by bringing for-
ward the date of diagnosis, thus resulting in a temporary increase 
in cancer incidence (  39  ). Once the program is in place and 
screening coverage of the target population reaches a plateau, inci-
dence rates tend to decrease because the pool of undiagnosed 
prevalent cases has been reduced (  28  ,  39  ). We found that the 
change point in breast cancer incidence in Spain occurred in 2001, 
but this overall trend is likely to be the consequence of changes 
acting on different age groups and regions at different times. 
Among women aged 45  –  64 years, a sharp downturn in breast 
  Table 2    .       Trends in age-adjusted incidence rates of invasive breast cancer among women aged 25 years or older included in Spanish 
registries with at least 15 years of uninterrupted registration  *     
    Cancer 
registry
Years 
covered
Screening program   
Change point, 
calendar year   
Annual percent change 
(95% CI)     
  Starting 
year
Full-coverage 
year   P      †    Estimate (95% CI) Overall
Before change 
point After change point   
    Navarra 
 (Navarre)
1980  –  2004 1990 1992 <.001 1991 (1989 to 1992)   —  5.1 (3.9 to 6.4) 0.3 (     0.5 to 1.1) 
  Asturias 1982  –  2003 1991 2000 .99   —  2.5 (2.1 to 2.8)   —   —   
  Zaragoza 1980  –  2003 1999 2006 .83   —  2.8 (2.4 to 3.2)   —   —   
  Tarragona 1980  –  2002 1998 2001 .99   —  1.9 (1.4 to 2.3)   —   —   
  Granada 1985  –  2004 1998 2003 .003 2002 (2001 to 2003)   —  3.6 (3.0 to 4.2)      9.0 (     14.7 to      2.8) 
  Murcia 1983  –  2001 1995 1999 .46   —  2.9 (2.5 to 3.4)   —   —   
  Bizkaia (Biscay) 1986  –  2004 1997 1999 <.001 1998 (1997 to 2000)   —  3.3 (2.6 to 4.1)      0.9 (     2.3 to 0.6) 
  Gipuzkoa 1986  –  2004 1997 1998 .001 1998 (1996 to 1999)   —  3.3 (2.3 to 4.3)      1.9 (     3.6 to      0.1) 
  Araba 1986  –  2004 1995 1997 .002 1997 (1994 to 1998)   —  4.7 (2.9 to 6.5)      1.8 (     3.9 to 0.3)   
    *     Trend changes were evaluated using change-point models (see “Methods”). Annual percent changes (95% CIs) over the entire covered periods are reported for 
registries with no evidence of change points, whereas the estimated change point (95% CI), together with the annual percent changes below and above it, is 
reported for registries with statistically significant trend changes. CI = confidence interval;   —   = not applicable.   
      †       Corrected asymptotic   P   value of the two-sided test for the existence of a change point in the overall trend (see “Methods”).     1590   Articles | JNCI  Vol. 101, Issue 22  |  November 18, 2009
cancer incidence was observed in 2001, when screening coverage 
ﬁ   rst exceeded 90% of the target population countrywide (  38  ). 
Incidence decreased thereafter, probably as a result of the dramatic 
decline in the pool of prevalent cases following the ﬁ  rst screening 
rounds. In older women, breast cancer incidence stabilized in 
1995. This phenomenon may be explained by early diagnosis of 
screen-detected tumors that otherwise would have been detected 
later. Moreover, screening also detects in situ carcinomas, which 
are surgically treated to prevent their progression into invasive 
tumors. Both factors  —  diagnostic anticipation and detection and 
treatment of preinvasive lesions  —  could have contributed to the 
reduced incidence we observed in the older age groups (  28  ). The 
same phenomenon has been described in the Netherlands (  33  ). 
  Our results for Spanish regions with a longer history of cancer 
registration also conﬁ  rm the inﬂ  uence of screening on breast 
cancer incidence trends. A statistically signiﬁ  cant interruption in 
the steady rise in breast cancer incidence was detected before 
2000 in Navarra and the three Basque Country provinces of Bizkaia, 
Gipuzkoa, and Araba. In all of these regions, breast cancer screening 
programs were fully implemented over fairly short periods and 
required only 1  –  2 years to achieve full coverage of the respective 
target populations. In addition, the overall participation rate in the 
ﬁ  rst and successive screening rounds was 88% in Navarra and 81% 
in the Basque Country provinces (  38  ), well above the desired level 
of 75% set by European guidelines to achieve an impact on the 
population (  37  ). In the remaining regions of Spain, full implemen-
tation of screening programs took longer and was achieved only 
recently, between 1999 and 2006 depending on the region. As a 
result, screening saturation was not observed during the study 
period, except in Granada, where it occurred in 2002. Furthermore, 
in some places where screening programs did not start until 
the late 1990s, such as in Tarragona, a substantial proportion of 
women had undergone screening in response to their gynecolo-
gist’s recommendation (ie, opportunistic screening) and so the 
screening program had a lower impact in terms of breast cancer 
incidence. 
  The recent increase in breast cancer incidence among Spanish 
women younger than 45 years calls for speciﬁ  c comment because 
in many other developed countries, breast cancer incidence among 
women in this age range has stabilized (  8  ,  10    –    14  ,  16  ,  18  ,  40  ,  41  ). 
Although women younger than 45 years are not formally included 
in Spanish screening programs, the widespread use of mammog-
raphy in gynecological clinics might nevertheless inﬂ  uence diag-
nosis in such women. According to the 2006 Spanish National 
Health Survey, only 4% of women aged 25  –  34 years reported 
regular use of mammography (ie, at least once every 2 years); 
among women aged 35  –  44 years, 19% reported regular mammog-
raphy use (  36  ). However, these percentages were substantially 
lower than the prevalence of mammography use of 62% and 84% 
observed for women aged 45  –  54 and 55  –  64 years, respectively, 
which suggests that regular mammographic examination cannot 
completely explain the upward trend in incidence observed among 
women younger than 45 years. A more plausible explanation for 
the continuous increase in breast cancer incidence among younger 
women may be the remarkable change in lifestyle that has taken 
place in Spain during the past two decades. For example, the 
decline in fertility that has been observed in all European countries 
was particularly sharp in Spain, where the average number of 
births per woman dropped from 2.9 in 1970 to 1.2 in 1995 (  4  ). 
Furthermore, the mean age at ﬁ  rst child’s birth was 25 years in 
1975, and by 2000, it had increased to 29 years (  42  ). An ecological 
study conducted in 34 industrialized countries found strong posi-
tive correlations above .75 between the average age at ﬁ  rst delivery 
and subsequent breast cancer risk, particularly among women 
younger than 45 years (  43  ). On the other hand, the mean age at 
menarche  —  a risk factor also associated with the development of 
breast cancer at younger ages (  44  )  —  has decreased at a higher rate 
in Spain than in other European countries (  45  ). In summary, the 
steadily rising trend in breast cancer incidence among the youngest 
group of women in Spain may be explained by a cohort effect 
linked to recent changes in reproductive and lifestyle factors. 
  At this point, it is difﬁ  cult to predict whether breast cancer 
incidence among Spanish women older than 45 years will continue 
to decrease in the near future, when all Spanish breast cancer 
screening programs will be fully consolidated and the youngest 
cohorts of women, who will have experienced these dramatic life-
style changes, are 60  –  70 years old. Premenopausal and postmeno-
pausal breast cancers have etiologies that differ somewhat from 
each other, and epidemiological evidence suggests that there are at 
least two types of breast tumors with different ages at onset (  46  ). 
Breast tumors in young women tend to be more aggressive and are 
characterized by less hormone sensitivity and higher expression of 
human epidermal growth factor receptor 2 and epithelial growth 
factor receptor (EGFR), whereas breast tumors that occur in older 
women tend to have estrogen receptors and lower human epider-
mal growth factor receptor 2 and epithelial growth factor receptor 
expression (  47  ) Statistical information systems are an important 
component of breast cancer control, and the continuous surveil-
lance carried out by Spanish cancer registries will shed light on the 
evolution of the breast cancer epidemic in the future.   
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